Dependence on Mdm2 for Mdm4 inhibition of p53 activity
Cancer Letters · 2025-07 · 621 · 217622
DOI: 10.1016/j.canlet.2025.217622 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025-07. Verfasst von Shunbin Xiong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, UT M.D. Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Proto-Oncogene Proteins c-mdm2, Proto-Oncogene Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Both Mdm2 and Mdm4 inhibit p53 activity by masking of its transcriptional activation domain. In addition, Mdm2 functions as an E3 ubiquitin ligase, targeting p53 for degradation. The amino terminus of Mdm4 binds wild type and mutant p53 while its RING domain, which lacks E3 ligase activity, is required for heterodimerization with Mdm2. To determine how these domains of Mdm4 regulate p53, we generated mouse models with either a deletion of the Mdm4 RING domain (Mdm4ΔR) or all of Mdm4 (Mdm4─) on a hypomorphic (p53neo) background. Mdm4ΔR mice exhibited elevated p53 levels and activity, albeit to a lesser extent than mice with complete Mdm4 loss, indicating that the amino terminus of Mdm4 contributes to p53 inhibition. Moreover, in the absence of Mdm2, neither the deletion of the Mdm4 RING domain nor the complete loss of Mdm4 further increased p53 protein levels on a mutant p53 background, indicating that Mdm4 modulates Mdm2 in its regulation of p53 stability. Collectively, our findings suggest that Mdm4 contributes to p53 inhibition by modulating Mdm2 activity via both its amino terminus and RING domains.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetics, UT M.D. Anderson Cancer Center, Houston, TX, USA.
- Department of Pharmaceutical Sciences, Joan M. Lafleur College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, 77004, USA.
- Department of Pediatrics, UT M.D. Anderson Cancer Center, Houston, TX, USA.
- Department of Hematopathology, UT M.D. Anderson Cancer Center, Houston, TX, USA.
- Department of Genetics, UT M.D. Anderson Cancer Center, Houston, TX, USA. Electronic address: gglozano@mdanderson.org.
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Institute of General Medical Sciences
Zitieren
APA
Xiong, S., Zhang, Y., Zhou, X., Pant, V., Mirani, A., Gencel-Augusto, J., Chau, G., You, M. J., & Lozano, G. (2025). Dependence on Mdm2 for Mdm4 inhibition of p53 activity. Cancer Letters, 621, 217622. https://doi.org/10.1016/j.canlet.2025.217622
Vancouver
Xiong S, Zhang Y, Zhou X, Pant V, Mirani A, Gencel-Augusto J, et al. Dependence on Mdm2 for Mdm4 inhibition of p53 activity. Cancer Letters. 2025;621:217622. doi:10.1016/j.canlet.2025.217622
BibTeX
@article{Xiong2025,
author = {Xiong, Shunbin and Zhang, Yun and Zhou, Xin and Pant, Vinod and Mirani, Akshita and Gencel-Augusto, Jovanka and Chau, Gilda and You, M James and Lozano, Guillermina},
title = {Dependence on Mdm2 for Mdm4 inhibition of p53 activity},
journal = {Cancer Letters},
year = {2025},
volume = {621},
pages = {217622},
doi = {10.1016/j.canlet.2025.217622}
}
EUVIMED